SG10201706741VA - Genetic modification of rats - Google Patents

Genetic modification of rats

Info

Publication number
SG10201706741VA
SG10201706741VA SG10201706741VA SG10201706741VA SG10201706741VA SG 10201706741V A SG10201706741V A SG 10201706741VA SG 10201706741V A SG10201706741V A SG 10201706741VA SG 10201706741V A SG10201706741V A SG 10201706741VA SG 10201706741V A SG10201706741V A SG 10201706741VA
Authority
SG
Singapore
Prior art keywords
rats
genetic modification
genetic
modification
Prior art date
Application number
SG10201706741VA
Inventor
Jeffrey D Lee
Wojtek Auerbach
David Heslin
David Frendewey
Ka-Man Venus Lai
David M Valenzuela
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10201706741VA publication Critical patent/SG10201706741VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/02—Breeding vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D19/00—Instruments or methods for reproduction or fertilisation
    • A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201706741VA 2013-02-20 2014-02-20 Genetic modification of rats SG10201706741VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361767093P 2013-02-20 2013-02-20

Publications (1)

Publication Number Publication Date
SG10201706741VA true SG10201706741VA (en) 2017-10-30

Family

ID=51351689

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201706741VA SG10201706741VA (en) 2013-02-20 2014-02-20 Genetic modification of rats
SG11201505968WA SG11201505968WA (en) 2013-02-20 2014-02-20 Genetic modification of rats

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201505968WA SG11201505968WA (en) 2013-02-20 2014-02-20 Genetic modification of rats

Country Status (15)

Country Link
US (5) US20140235933A1 (en)
EP (2) EP3561050B1 (en)
JP (2) JP6475172B2 (en)
KR (1) KR102209979B1 (en)
CN (2) CN109913495B (en)
AU (1) AU2014218931C1 (en)
BR (1) BR112015019950B1 (en)
CA (1) CA2900992C (en)
ES (2) ES2904803T3 (en)
HK (1) HK1214627A1 (en)
IL (1) IL240286A0 (en)
MX (2) MX2015010841A (en)
RU (1) RU2690352C2 (en)
SG (2) SG10201706741VA (en)
WO (1) WO2014130706A1 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
DK2847335T3 (en) 2012-04-25 2018-08-13 Regeneron Pharma NUCLEASED MEDIUM TARGETING WITH LARGE TARGET VECTORS
ES2728782T3 (en) 2012-05-25 2019-10-28 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
KR102243092B1 (en) 2012-12-06 2021-04-22 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-based genome modification and regulation
SG10201706741VA (en) 2013-02-20 2017-10-30 Regeneron Pharma Genetic modification of rats
PL3456831T3 (en) 2013-04-16 2021-12-06 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
JP6998656B2 (en) 2013-08-07 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド lincRNA deletion non-human animal
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
RU2685914C1 (en) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Methods and compositions for genome targeted modification
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2877275T3 (en) 2014-05-30 2021-11-16 Regeneron Pharma Animals with humanized dipeptidyl peptidase IV (DPP4)
KR102374379B1 (en) 2014-06-06 2022-03-17 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for modifying a targeted locus
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
PL3221457T3 (en) 2014-11-21 2019-09-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
MX2017007636A (en) 2014-12-09 2018-03-28 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 274 gene.
WO2016100819A1 (en) 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification through single-step multiple targeting
SG11201706809WA (en) 2015-03-16 2017-09-28 Regeneron Pharma Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
BR112017025507A2 (en) 2015-05-29 2018-08-07 Regeneron Pharmaceuticals, Inc. rodent, isolated rodent cell or isolated rodent tissue, rodent embryonic stem cell, rodent embryo, and methods for preparing a rodent and for identifying a therapeutic candidate.
JP2018526005A (en) 2015-09-02 2018-09-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． A rodent model of prostate cancer
JP7067793B2 (en) 2015-10-23 2022-05-16 プレジデント アンド フェローズ オブ ハーバード カレッジ Nucleobase editing factors and their use
CN105684993B (en) * 2016-02-01 2018-06-01 江苏大学 GABAergic neurons conditionity knocks out the preparation of gene PGC-1 α mouse
WO2017136712A1 (en) 2016-02-04 2017-08-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
KR20180110107A (en) 2016-02-16 2018-10-08 리제너론 파마슈티칼스 인코포레이티드 Non-human animal with the mutated quinoleninase gene
CN109068621B (en) 2016-02-29 2021-07-20 再生元制药公司 Rodent with humanized TMPRSS gene
EP4368637A2 (en) 2016-05-20 2024-05-15 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
MX2019001211A (en) 2016-07-29 2019-09-16 Regeneron Pharma Mice comprising mutations resulting in expression of c-truncated fibrillin-1.
JP7231935B2 (en) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Adenosine nucleobase editors and their uses
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG10202102997UA (en) 2016-09-30 2021-04-29 Regeneron Pharma Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus
KR20240007715A (en) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Aav delivery of nucleobase editors
SG11201903344XA (en) 2016-11-04 2019-05-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
CN106636000A (en) * 2016-12-23 2017-05-10 广东圣赛生物科技有限公司 hESCs-TK cell line and building method and application thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
MX2019008755A (en) 2017-01-23 2019-12-16 Regeneron Pharma Hsd17b13 variants and uses thereof.
US11064685B2 (en) 2017-02-27 2021-07-20 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
KR20190130613A (en) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Nucleobase edits comprising nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
EP3644722A1 (en) 2017-06-27 2020-05-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized asgr1 locus
JP2020534795A (en) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods and Compositions for Evolving Base Editing Factors Using Phage-Supported Continuous Evolution (PACE)
JP7359753B2 (en) 2017-07-31 2023-10-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Embryonic stem cells of Cas transgenic mice and mice and their uses
KR20200032117A (en) 2017-07-31 2020-03-25 리제너론 파마슈티칼스 인코포레이티드 Evaluation of CRISPR / Cas-induced recombination with exogenous donor nucleic acids in vivo
SG11201912236YA (en) 2017-07-31 2020-01-30 Regeneron Pharma Crispr reporter non-human animals and uses thereof
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus and methods of use
PT3687287T (en) 2017-09-29 2023-11-03 Regeneron Pharma Non-human animals expressing humanized c1q complex
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
CA3076371C (en) 2017-11-10 2022-11-22 Regeneron Pharmaceuticals, Inc. Non-human animals comprising slc30a8 mutation and methods of use
EP3585164B1 (en) 2017-11-30 2023-12-27 Regeneron Pharmaceuticals, Inc. Rats comprising a humanized trkb locus
CA3084049A1 (en) 2017-12-05 2019-06-13 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
CA3089331A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
KR20200135397A (en) 2018-03-24 2020-12-02 리제너론 파마슈티칼스 인코포레이티드 Genetically modified non-human animals for producing therapeutic antibodies against peptide-MHC complexes, methods of making the same
US10463029B1 (en) 2018-06-07 2019-11-05 Regeneron Pharmaceuticals, Inc. Rodent model of steel syndrome
CA3099441A1 (en) 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
AU2019308205A1 (en) 2018-07-16 2020-11-19 Regeneron Pharmaceuticals, Inc. Non-human animal models of DITRA disease and uses thereof
US20220053741A1 (en) 2018-09-13 2022-02-24 Regeneron Pharmaceuticals, Inc. Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
CN116064550A (en) 2018-12-20 2023-05-05 瑞泽恩制药公司 Nuclease-mediated repeat amplification
JP2022517101A (en) 2019-01-17 2022-03-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Rodents model of mood disorders
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
KR20210141964A (en) 2019-03-15 2021-11-23 리제너론 파마슈티칼스 인코포레이티드 Loss of function of solute carrier 39 member 5 rodent model
EP3942040A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
JP7379528B2 (en) * 2019-03-26 2023-11-14 ツールジェン・インコーポレイテッド Hemophilia B disease model rat
EP3945800A1 (en) 2019-04-03 2022-02-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
AU2020253532A1 (en) 2019-04-04 2021-09-02 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
KR20220016869A (en) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 Non-Human Animals Comprising a Humanized TTR Locus with Beta-Slip Mutations and Methods of Use
BR112021023683A2 (en) 2019-06-05 2022-02-01 Regeneron Pharma Genetically modified rodent and mouse, rodent embryo, genetically modified rodent or mouse b-cell, hybridoma, b-cell population, embryonic stem cell, mammalian cell, methods of producing an antibody, a heavy chain, a domain variable, from a collection of variable domains, from a light chain, from a nucleotide sequence, from a genetically modified rodent and from es cells, from generating a variable domain and in vitro to generate a recombinant rodent cell, and, vector of direction
JP2022534560A (en) 2019-06-07 2022-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Non-human animals containing humanized albumin loci
JP2022536606A (en) 2019-06-14 2022-08-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Model of tauopathy
CN114008193A (en) 2019-06-27 2022-02-01 瑞泽恩制药公司 Modeling of TDP-43 proteinopathies
KR20220062079A (en) 2019-09-13 2022-05-13 리제너론 파마슈티칼스 인코포레이티드 Transcriptional Regulation in Animals Using the CRISPR/Cas System Delivered by Lipid Nanoparticles
US11825819B2 (en) 2019-10-03 2023-11-28 Regeneron Pharmaceuticals, Inc. Crnn loss of function rodent model
EP4054651A1 (en) 2019-11-08 2022-09-14 Regeneron Pharmaceuticals, Inc. Crispr and aav strategies for x-linked juvenile retinoschisis therapy
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
AU2021212668A1 (en) 2020-01-28 2022-08-18 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized PNPLA3 locus and methods of use
US20230081547A1 (en) 2020-02-07 2023-03-16 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized klkb1 locus and methods of use
TW202145884A (en) 2020-03-04 2021-12-16 美商再生元醫藥公司 A rodent model of b4galt1-mediated functions
US20230102342A1 (en) 2020-03-23 2023-03-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
JP2023523174A (en) 2020-04-21 2023-06-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Non-human animals with humanized CXCL13 gene
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
EP4171215A2 (en) 2020-06-26 2023-05-03 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
CA3191836A1 (en) 2020-10-01 2022-04-07 Andrew J. Murphy Rodent animals expressing human cr1
KR20230124973A (en) 2020-12-21 2023-08-28 리제너론 파마슈티칼스 인코포레이티드 Non-human animals having a humanized TSLP gene, a humanized TSLP receptor gene, and/or a humanized IL7RA gene
KR20240008354A (en) * 2021-05-18 2024-01-18 유니버시티 오브 써던 캘리포니아 Method for expansion of human granulocyte-macrophage precursors and application thereof
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
AU2022381205A1 (en) 2021-11-04 2024-03-28 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified cacng1 locus
WO2023108047A1 (en) 2021-12-08 2023-06-15 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023122506A1 (en) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci
WO2023150798A1 (en) 2022-02-07 2023-08-10 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
WO2023154861A1 (en) 2022-02-11 2023-08-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for screening 4r tau targeting agents
WO2023212560A1 (en) 2022-04-26 2023-11-02 Regeneron Pharmaceuticals, Inc. A rodent model of fibrodysplasia ossificans progressiva
WO2023235725A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr-based therapeutics for c9orf72 repeat expansion disease
WO2023235726A2 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Crispr interference therapeutics for c9orf72 repeat expansion disease
WO2023235677A1 (en) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Animal model of tdp-43 proteinopathy
US20230417899A1 (en) 2022-06-27 2023-12-28 Oshkosh Corporation Position tracking for a lift device
US20240102045A1 (en) 2022-07-19 2024-03-28 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2024026488A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
US20240130341A1 (en) 2022-09-29 2024-04-25 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (en) 1987-04-02 1992-07-31 Amrad Corp Ltd METHOD OF PURIFICATION OF THE LEUKEMIA INHIBITOR FACTOR (LIF) AND PHARMACEUTICAL COMPOSITIONS CONTAINING POLIPEPTIDES WITH LIF ACTIVITY
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
AU7677894A (en) * 1993-08-30 1995-03-22 Northwestern University Rat pluripotent embryonic stem cells and method of obtaining and using same
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
CA2246712A1 (en) * 1996-02-16 1997-08-21 The University Of Edinburgh Cytokine expressed by dia/lif-deficient embryonic stem cells for the inhibition of differentiation
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6136566A (en) 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
JP2002533130A (en) 1998-12-31 2002-10-08 ザ ジェイ． デビッド グラッドストーン インスティテューツ Transgenic rodents and rodent cell lines expressing HIV co-receptors
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002046412A2 (en) 2000-12-07 2002-06-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US9234187B2 (en) 2001-01-22 2016-01-12 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US7947469B2 (en) 2001-01-22 2011-05-24 Gendaq, Ltd. Modulation of HIV infection
NZ527527A (en) * 2001-02-14 2005-08-26 Leo T Mammalian multipotent adult stem cells (MASC) with the capacity to differentiate into cells of mesodermal, ectodermal or endodermal origin and uses thereof
ATE347593T1 (en) 2002-01-23 2006-12-15 Univ Utah Res Found TARGETED CHROMOSOMAL MUTAGENESIS WITH ZINC FINGER NUCLEASES
DE60316124T3 (en) 2002-03-15 2018-03-22 Cellectis HYBRID AND SINGLE CHAIN MEGANUCLEASES AND ITS APPLICATIONS
EP2368982A3 (en) 2002-03-21 2011-10-12 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
WO2004037977A2 (en) 2002-09-05 2004-05-06 California Institute Of Thechnology Use of chimeric nucleases to stimulate gene targeting
WO2004031346A2 (en) 2002-09-06 2004-04-15 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP4862119B2 (en) 2004-03-04 2012-01-25 大日本住友製薬株式会社 Rat embryonic stem cells
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
ATE510006T1 (en) 2004-09-03 2011-06-15 Moraga Biotechnology Inc BLASTOMER-LIKE NON-EMBRYONAL TOTIPOTENT STEM CELLS AND METHODS OF COLLECTION AND USE
EP1789095A2 (en) 2004-09-16 2007-05-30 Sangamo Biosciences Inc. Compositions and methods for protein production
CA2583750C (en) 2004-10-19 2015-11-24 Regeneron Pharmaceuticals, Inc. Methods for generating a rodent having a genetic modification
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2006097854A1 (en) 2005-03-15 2006-09-21 Cellectis Heterodimeric meganucleases and use thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
TW200815597A (en) 2006-03-30 2008-04-01 Univ Edinburgh Culture medium containing kinase inhibitors, and uses thereof
JP5514539B2 (en) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
KR101613624B1 (en) 2006-12-14 2016-04-29 다우 아그로사이언시즈 엘엘씨 Optimized non-canonical zinc finger proteins
US7771967B2 (en) 2006-12-22 2010-08-10 The J. David Gladstone Institutes Nucleic acid encoding apolipoprotein E-I3
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
KR101909847B1 (en) * 2008-12-17 2018-12-18 더 스크립스 리서치 인스티튜트 Generation and maintenance of stem cells
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
AU2010226313B2 (en) 2009-03-20 2014-10-09 Sangamo Therapeutics, Inc. Modification of CXCR4 using engineered zinc finger proteins
US8722964B2 (en) 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
EP2456876A2 (en) 2009-07-24 2012-05-30 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for cytokine-cytokine signaling pathways
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US8354389B2 (en) * 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
EP2508595B1 (en) * 2009-12-01 2016-11-23 National Cancer Center Method for constructing chimeric rat using rat embryonic stem cells
ES2527997T5 (en) 2009-12-10 2018-05-17 Regents Of The University Of Minnesota DNA modification induced by the TAL effector
JP2011152111A (en) * 2010-01-28 2011-08-11 Univ Of Fukui Culture medium for culturing pluripotent stem cell
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
DK2847335T3 (en) 2012-04-25 2018-08-13 Regeneron Pharma NUCLEASED MEDIUM TARGETING WITH LARGE TARGET VECTORS
ES2728782T3 (en) 2012-05-25 2019-10-28 Univ California Methods and compositions for RNA-directed target DNA modification and for RNA-directed transcription modulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2013359212B2 (en) 2012-12-12 2017-01-19 Massachusetts Institute Of Technology Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
SG10201706741VA (en) 2013-02-20 2017-10-30 Regeneron Pharma Genetic modification of rats
PL3456831T3 (en) 2013-04-16 2021-12-06 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
DE202014010413U1 (en) 2013-09-18 2015-12-08 Kymab Limited Cells and organisms
RU2685914C1 (en) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Methods and compositions for genome targeted modification
AU2014361781B2 (en) 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
AU2015218576B2 (en) 2014-02-24 2020-02-27 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration
KR102374379B1 (en) 2014-06-06 2022-03-17 리제너론 파마슈티칼스 인코포레이티드 Methods and compositions for modifying a targeted locus
PT3161128T (en) 2014-06-26 2018-11-21 Regeneron Pharma Methods and compositions for targeted genetic modifications and methods of use
PL3221457T3 (en) 2014-11-21 2019-09-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas

Also Published As

Publication number Publication date
SG11201505968WA (en) 2015-08-28
US10894965B2 (en) 2021-01-19
ES2758477T3 (en) 2020-05-05
RU2019114118A3 (en) 2021-12-29
CN109913495A (en) 2019-06-21
EP3561050A1 (en) 2019-10-30
EP2958990A4 (en) 2016-07-13
JP6475172B2 (en) 2019-02-27
CA2900992A1 (en) 2014-08-28
AU2014218931A1 (en) 2015-09-10
CN105121631A (en) 2015-12-02
EP3561050B1 (en) 2021-12-08
IL240286A0 (en) 2015-09-24
RU2690352C2 (en) 2019-05-31
US20160108360A1 (en) 2016-04-21
CN109913495B (en) 2022-11-25
WO2014130706A1 (en) 2014-08-28
US20210130846A1 (en) 2021-05-06
CN105121631B (en) 2019-04-19
RU2015139350A (en) 2017-03-24
ES2904803T3 (en) 2022-04-06
AU2014218931C1 (en) 2020-05-14
JP2016507250A (en) 2016-03-10
JP6758440B2 (en) 2020-09-23
EP2958990B1 (en) 2019-10-16
HK1214627A1 (en) 2016-07-29
KR20150119384A (en) 2015-10-23
BR112015019950B1 (en) 2023-02-14
US20140235933A1 (en) 2014-08-21
KR102209979B1 (en) 2021-02-01
MX2015010841A (en) 2016-05-09
JP2019062924A (en) 2019-04-25
CA2900992C (en) 2023-02-28
US10329582B2 (en) 2019-06-25
US20170037429A1 (en) 2017-02-09
NZ711775A (en) 2021-02-26
AU2014218931B2 (en) 2020-01-23
EP2958990A1 (en) 2015-12-30
RU2019114118A (en) 2019-05-31
MX2019015525A (en) 2020-02-13
BR112015019950A2 (en) 2017-08-29
US20190316149A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
HRP20211385T8 (en) Targeted modification of rat genome
HK1214627A1 (en) Genetic modification of rats
HK1222466A1 (en) Analysis of genetic variants
HRP20182063T1 (en) Rhizomania-resistant gene
SG11201506876XA (en) Modification of polypeptides
EP3049079A4 (en) Solid forms of ceftolozane
GB201310558D0 (en) Genetic test
GB201300632D0 (en) Discovery
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
PL3071575T3 (en) Preparation of normorphinans
HK1198422A1 (en) Novel uses of colossolactones
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling
GB201304608D0 (en) BenTime of Yisrael operable arrangement
HUP1300040A2 (en) Gluten-free flourmix
HUE036665T2 (en) Solid form of dihydro-pyrido-oxazine derivative
TWM476725U (en) Structure of wheelbarrow